An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma — Stella

Recruiting

Back to Neuroblastoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

Prinses Maxima Centrum, Utrecht

Key details

Phase

Early testing / Safety & dosing

Sponsor

Princess Maxima Center for Pediatric Oncology

Enrollment target

~22 participants

Started

November 2025

Primary completion

April 2027

Age range

1 Year – 18 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov